Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 46

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 14, 2024; 30(46): 4904-4913
Published online Dec 14, 2024. doi: 10.3748/wjg.v30.i46.4904

Table 4 Treatment persistence subgroup analysis in patients with ulcerative colitis and Crohn’s disease, n (%)

Inflammatory bowel disease subtype			Treatment persistence by 30 months	Treatment discontinuation by 30 months	Total	P value
Ulcerative colitis	Drug group	Biosimilar	31 (86.1)	5 (13.9)	36	1.0
		Originator	7 (87.5)	1 (12.5)	8
	Total		36	6	44
Crohn’s disease	Drug group	Biosimilar	170 (88.5)	22 (11.5)	192	0.400
		Originator	29 (82.9)	6 (17.1)	35
	Total		199	28	227
Total	Drug group	Biosimilar	201 (88.2)	27 (11.8)	228	0.451
		Originator	36 (83.7)	7 (16.3)	43
	Total		237	34	271

Citation: Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2024; 30(46): 4904-4913
URL: https://www.wjgnet.com/1007-9327/full/v30/i46/4904.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i46.4904

Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2024; 30(46): 4904-4913 [PMID: 39679312 DOI: 10.3748/wjg.v30.i46.4904]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.